Evofem signs exclusive 5-year distributorship for SOLOSEC in sub-Saharan Africa with Clovis Davis

Evofem Biosciences, Inc.

Exclusive 5-year distribution agreement with Clovis Davis for SOLOSEC in sub-Saharan Africa, effective April 24, 2026.
SOLOSEC is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.
Clovis Davis to lead distribution, promotion, and sales; regulatory filings based on US FDA dossier.
BV affects ~25% of women in sub-Saharan Africa; 10.9M women eligible in Ethiopia alone.
No upfront payments or financial terms disclosed; partnership aims to expand global reach.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Evofem Biosciences, Inc. entered into Distributorship Agreement with Clovis Davis Pharmaceuticals, LLC. (effective 2026-04-24).

Action: entry
Agreement: supply
Counterparty: Clovis Davis Pharmaceuticals, LLC.
Effective: 2026-04-24

Exact text from the filing

On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.

View on SEC.gov

Browse all material agreements →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-020417

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.